title: Can we use Sorafenib for advanced Hepatocellular Carcinoma (HCC) Child Pugh B?
abstract: HCC is the third cause of cancer-related death worldwide and the fifth most common cancer in the world with an increasing incidence in some areas like Europe, USA and the Gulf region. In this study patients with advanced HCC in both group child pugh A and B were treated with sorafenib.
  
  
  METHODS
  This is a retrospective observational study to assess the safety and effectiveness of sorafenib in patients with advanced HCC child pugh A and B who failed local palliative ablation therapy or were not eligible for such therapy. Forty six patients included.
  
  
  RESULTS
  In both child pugh A and B group the sorafenib was well tolerated and survival was improved but it was more pronounced in the child pugh A group.
  
  
  CONCLUSIONS
  This is the first study that includes high percentage (47%) of child B group to be treated with sorafenib. Compared with international data there was improved overall survival in both groups.
authors: NCCCR, Hamad Medical Corporation, Doha, Qatar.
authors: K
authors: K
authors: Rasul
authors: NCCCR, Hamad Medical Corporation, Doha, Qatar.
authors: A
authors: A
authors: Issameldin
authors: NCCCR, Hamad Medical Corporation, Doha, Qatar.
authors: S
authors: S
authors: Elazzazi
authors: NCCCR, Hamad Medical Corporation, Doha, Qatar.
authors: R
authors: R
authors: Ghasoub
authors: NCCCR, Hamad Medical Corporation, Doha, Qatar.
authors: A
authors: A
authors: Gulied